Latest news with #EranOphir
Yahoo
20-05-2025
- Business
- Yahoo
Compugen Ltd (CGEN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline
Cash Balance: Approximately $103.7 million as of March 31, 2025. Revenue: Approximately $2.3 million for Q1 2025, compared to $2.6 million in Q1 2024. R&D Expenses: Approximately $5.8 million for Q1 2025, compared to $6.4 million in Q1 2024. G&A Expenses: Approximately $2.4 million for both Q1 2025 and Q1 2024. Net Loss: Approximately $7.2 million or $0.08 per share for Q1 2025, compared to $7.3 million or $0.08 per share in Q1 2024. Cash Runway: Expected to fund operating plans into 2027. Warning! GuruFocus has detected 3 Warning Signs with CGEN. Release Date: May 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Compugen Ltd (NASDAQ:CGEN) has initiated a sub-trial for their anti-PVRIG antibody COM701 in ovarian cancer, targeting an unmet medical need. The company has a strong cash position with a runway extending into 2027, supporting their clinical and research activities. Compugen Ltd (NASDAQ:CGEN) is advancing its early-stage and clinical immuno-oncology pipeline, focusing on innovative therapies. Partnership with AstraZeneca is progressing, with multiple Phase 3 trials initiated, potentially leading to significant revenue opportunities. The company is exploring novel mechanisms of action in their early-stage pipeline, aiming to enhance anticancer immunity. Revenues for the first quarter of 2025 decreased compared to the same period in 2024. The company reported a net loss of approximately $7.2 million for the first quarter of 2025. There is uncertainty in the TIGIT landscape, with previous Phase 3 failures impacting market sentiment. The success of Compugen Ltd (NASDAQ:CGEN)'s TIGIT program is contingent on positive outcomes from upcoming Phase 3 trials. The competitive landscape in ovarian cancer is evolving, with new therapies potentially impacting Compugen Ltd (NASDAQ:CGEN)'s strategy. Q: Merck's KEYNOTE-B96 Phase 3 study in pembrolizumab for platinum-resistant ovarian cancer was successful. How might this impact your strategy in ovarian cancer? A: Michelle Mahler, Chief Medical Officer: The study is in a different setting, but it shows benefit from adding an immune checkpoint inhibitor. If our study demonstrates activity, it could open opportunities to combine COM701 in broader populations. Q: What is your interpretation of Roche's SKYCRAPER-01 data, and how does it affect your confidence in TIGIT antagonism? A: Eran Ophir, Vice President - Research, Drug Discovery: Despite the failure, we see numerical activity in TIGIT trials. The Fc active format may have contributed to high discontinuation rates. We believe Fc inactive antibodies, like ours, may offer safety and efficacy advantages. Q: Do you plan to collect data on tumor microenvironment features in the COM701 study? What PFS benefit would be clinically meaningful in the maintenance setting? A: Michelle Mahler, Chief Medical Officer: We will collect data on the tumor microenvironment but won't disclose details. An improvement of around three months in progression-free survival would be clinically meaningful. Q: Have you observed activity of COM701 in PD-L1 positive patients, and what are your thoughts on PD-1 VEGF bispecifics? A: Michelle Mahler, Chief Medical Officer: We see activity in both PD-L1 positive and negative patients. Eran Ophir, Vice President - Research, Drug Discovery: VEGF increases T cell infiltration, complementing PVRIG biology. Fc inactive TIGIT may be preferable for combinations due to safety concerns. Q: What are your thoughts on the potential synergy between TIGIT, PD-1, and VEGF inhibitors? A: Eran Ophir, Vice President - Research, Drug Discovery: VEGF can enhance T cell infiltration, aligning with PVRIG biology. While we haven't published data, combining with Fc inactive TIGIT could be advantageous due to safety profiles. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
19-05-2025
- Business
- Yahoo
Compugen Announces Leadership Transitions Effective September 2025
Anat Cohen-Dayag, Ph.D., appointed as Executive Chair of the Board of Directors Eran Ophir, Ph.D., appointed as President and Chief Executive Officer and will join the Board of Directors Paul Sekhri to step down as Chair of the Board of Directors HOLON, Israel, May 13, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced key leadership transitions to take effect in September 2025 following the Annual General Meeting. Anat Cohen-Dayag, Ph.D., currently President and Chief Executive Officer will assume the newly created role of Executive Chair of the Board of Directors, subject to shareholder approval. Eran Ophir, Ph.D., currently Chief Scientific Officer, has been appointed President and Chief Executive Officer and will join the Board of Directors, subject to shareholder approval. Paul Sekhri will step down as Chair of the Board of Directors. Dr. Cohen-Dayag has led Compugen as President and CEO since 2010. Under her leadership, the Company transformed into a therapeutic discovery and development company advancing a differentiated immuno-oncology pipeline based on Unigen™, Compugen's proprietary AI/ML-driven computational discovery platform. The Company's clinical-stage assets include the wholly owned COM701 and COM902, and milestone and royalty-bearing rilvegostomig (partnered with AstraZeneca, an Fc-reduced PD-1/TIGIT bispecific, the TIGIT component of which is derived from COM902), and GS-0321 (previously COM503, partnered with Gilead). In her new role as Executive Chair, Dr. Cohen-Dayag will focus on Compugen's corporate strategy, strategic collaborations, and be involved in investor relations. Paul Sekhri, outgoing Chair of the Board, stated, "As I step down as Chair of the Board after 8 years in the position, I do so with full confidence that Compugen is in exceptional hands. The leadership of Anat as Executive Chair and Eran as President and CEO ensures a strong foundation for the Company's next phase of growth." Dr. Cohen-Dayag commented, "I am proud of all we have accomplished: advancing an innovative clinical immunotherapy pipeline, establishing strategic collaborations, and building a robust foundation with a talented management team and a cash runway into 2027. This is the right moment to pass the leadership to Eran, who has been my trusted partner and Compugen's scientific leader for the past five years. His scientific and strategic contributions, including in our recent partnership with Gilead, have been pivotal. I look forward to continuing our success as I shift to a more strategic role. I would also like to thank Paul for his guidance, expertise and significant contributions throughout his tenure as Chair." Dr. Ophir has served in various managerial and executive roles at Compugen for nearly a decade. As Chief Scientific Officer, he has led research and discovery efforts and played a central role in building the Company's innovative immuno-oncology pipeline and corporate strategy. Dr. Cohen-Dayag continued, "Compugen's core strength lies in our ability to discover novel drug targets and advance proprietary novel drug candidates into clinical development, independently or through strategic partnerships. Eran's scientific expertise, strategic and operational leadership, and deep understanding of our pipeline make him uniquely positioned to lead the Company forward. The Board and I are confident this will be a seamless transition." Dr. Ophir, incoming President and CEO said, "I am both excited and honored to accept the responsibility of leading Compugen. I am grateful to the Board for their trust and to Anat who has been, and will continue to be, a valued mentor. I am proud of what we have accomplished, building an innovative clinical pipeline, securing impactful partnerships and working on bringing meaningful benefit to patients. I look forward to continuing to work with Anat and our exceptional team to take Compugen to new levels of innovation and success." About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. Forward-Looking StatementThis press release contains "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations, and assumptions of Compugen. Forward-looking statements can be identified using terminology such as "will," "may," "expects," "anticipates," "believes," "potential," "plan," "goal," "estimate," "likely," "should," "confident," and "intends," and similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, statements regarding our expectations regarding the leadership transitions and their results; statements regarding the Company's Annual General Meeting expected to be held in September 2025; statements regarding advancing a differentiated immuno-oncology pipeline based on Unigen™; statements regarding the Company's growth strategy and plans; statements regarding the Company's innovative clinical immunotherapy pipeline, strategic collaborations and robust foundation; and statements regarding the Company's cash runway. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance, or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: the clinical trials of any product candidates that Compugen, or any current or future collaborators, may develop may fail to satisfactorily demonstrate safety and efficacy to the FDA, and Compugen, or any collaborators, may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of these product candidates; Compugen's business model is substantially dependent on entering into collaboration agreements with third parties and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model; Compugen's approach to the discovery of therapeutic products is based on its proprietary computational target discovery infrastructure, which is unproven clinically; general market, political and economic conditions in the countries in which Compugen operates, including Israel; the effect of the evolving nature of the recent war in Israel; and Compugen does not know whether it will be able to discover and develop additional potential product candidates or products of commercial value. These risks and other risks are more fully discussed in the "Risk Factors" section of Compugen's most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law. Company contact:Yvonne Naughton, of Investor Relations and Corporate CommunicationsEmail: ir@ +1 (628) 241-0071 View original content: SOURCE Compugen Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
